Head and neck cancer
|Head and neck cancer|
|Cancer of the tongue with surrounding lichen planus|
|Symptoms||Lump or sore that does not heal, sore throat that does not go away, trouble swallowing, change in the voice|
|Risk factors||Alcohol, tobacco, betel quid, human papillomavirus, radiation exposure, certain workplace exposures, Epstein-Barr virus|
|Diagnostic method||Tissue biopsy|
|Prevention||Not using tobacco or alcohol|
|Treatment||Surgery, radiation therapy, chemotherapy, targeted therapy|
|Frequency||5.5 million (affected during 2015)|
Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands. Symptoms for head and neck cancer may include a lump or sore that does not heal, a sore throat that does not go away, trouble swallowing, or a change in the voice. There may also be unusual bleeding, facial swelling, or trouble breathing.
About 75% of head and neck cancer is caused by the use of alcohol or tobacco. Other risk factors include betel quid, certain types of human papillomavirus, radiation exposure, certain workplace exposures, and Epstein-Barr virus. Head and neck cancers are most commonly of the squamous cell carcinoma type. The diagnosis is confirmed by tissue biopsy. The degree of spread may be determined by medical imaging and blood tests.
Not using tobacco or alcohol can reduce the risk for head and neck cancer. While screening in the general population does not appear to be useful, screening high risk groups by examination of the throat might be useful. Head and neck cancer often is curable if it is diagnosed early; however, outcomes are typically poor if it is diagnosed late. Treatment may include a combination of surgery, radiation therapy, chemotherapy, and targeted therapy. Following treatment of one head and neck cancer, people are at higher risk of having a second cancer.
In 2015, head and neck cancers globally affected more than 5.5 million people (2.4 million mouth, 1.7 million throat, and 1.4 million larynx cancer), and it has caused over 379,000 deaths (146,000 mouth, 127,400 throat, 105,900 larynx cancer). Together, they are the seventh most-frequent cancer and the ninth most-frequent cause of death from cancer. In the United States, about 1% of people are affected at some point in their life, and males are affected twice as often as females. The usual age at diagnosis is between 55 and 65 years old. The average 5-year survival following diagnosis in the developed world is 42-64%.
- 1 Signs and symptoms
- 2 Causes
- 3 Diagnosis
- 4 Prevention
- 5 Management
- 6 Prognosis
- 7 Epidemiology
- 8 Research
- 9 References
- 10 External links
Signs and symptoms
Head and neck cancer usually begins with symptoms that seem harmless enough, like an enlarged lymph node on the outside of the neck, a sore throat, or a hoarse-sounding voice. However, in the case of head and neck cancer, these conditions may persist and become chronic. There may be a lump or a sore in the throat or neck that does not heal or go away. There may be difficult or painful swallowing. Speaking may become difficult. There may even be a persistent earache as well. Other possible but less-common symptoms include some numbness or paralysis of the face muscles.
Presenting symptoms include:
- Mass in the neck
- Neck pain
- Bleeding from the mouth
- Sinus congestion, especially with nasopharyngeal carcinoma
- Bad breath
- Sore tongue
- Painless ulcer or sores in the mouth that do not heal
- White, red, or dark patches in the mouth that will not go away
- Unusual bleeding or numbness in the mouth
- Lump in the lip, mouth or gums
- Enlarged lymph glands in the neck
- Slurring of speech (if the cancer is affecting the tongue)
- Hoarse voice which persists for more than six weeks
- Sore throat which persists for more than six weeks
- Difficulty swallowing food
- Change in diet or weight loss
Squamous cell cancers are common in areas of the mouth, including the inner lip, tongue, floor of mouth, gingivae, and hard palate. Cancers of the mouth are strongly associated with tobacco use, especially use of chewing tobacco or "dip", as well as heavy alcohol use. Cancers of this region, particularly the tongue, are more frequently treated with surgery than are other head and neck cancers.
Surgeries for oral cancers include:
- Maxillectomy (can be done with or without orbital exenteration)
- Mandibulectomy (removal of the lower jaw or part of it)
- Glossectomy (tongue removal, can be total, hemi or partial)
- Radical neck dissection
- Mohs procedure
- Combinational e.g., glossectomy and laryngectomy done together.
The defect is typically covered/improved by using another part of the body and/or skin grafts and/or wearing a prosthesis.
Nasopharyngeal cancer arises in the nasopharynx, the region in which the nasal cavities and the Eustachian tubes connect with the upper part of the throat. While some nasopharyngeal cancers are biologically similar to the common HNSCC, "poorly differentiated" nasopharyngeal carcinoma is lymphoepithelioma, which is distinct in its epidemiology, biology, clinical behavior, and treatment, and is treated as a separate disease by many experts.
Oropharyngeal squamous cell carcinomas (OSCC) begins in the oropharynx (throat), the middle part of the throat that includes the soft palate, the base of the tongue, and the tonsils. Squamous cell cancers of the tonsils are more strongly associated with human papillomavirus infection than are cancers of other regions of the head and neck. HPV-positive oropharyngeal cancer generally has a better outcomes than HPV-negative disease with a 54% better survival, but this advantage for HPV associated cancer applies only to oropharyngeal cancers.
People with oropharyngeal carcinomas are at high risk of developing second primary head and neck cancer.
The hypopharynx includes the pyriform sinuses, the posterior pharyngeal wall, and the postcricoid area. Tumors of the hypopharynx frequently have an advanced stage at diagnosis, and have the most adverse prognoses of pharyngeal tumors. They tend to metastasize early due to the extensive lymphatic network around the larynx.
Laryngeal cancer begins in the larynx or "voice box." Cancer may occur on the vocal folds themselves ("glottic" cancer), or on tissues above and below the true cords ("supraglottic" and "subglottic" cancers respectively). Laryngeal cancer is strongly associated with tobacco smoking.
Surgery can include laser excision of small vocal cord lesions, partial laryngectomy (removal of part of the larynx) or total laryngectomy (removal of the whole larynx). If the whole larynx has been removed, the person is left with a permanent tracheostomy. Voice rehabilitation in such patients can be achieved through three important ways - esophageal speech, tracheoesophageal puncture, or electrolarynx. One would likely require the help of intensive teaching and speech therapy and/or an electronic device.
Cancer of the trachea is a rare cancer which can be similar to head and neck cancer, and is sometimes classified as such.
Most tumors of the salivary glands differ from the common carcinomas of the head and neck in cause, histopathology, clinical presentation, and therapy. Other uncommon tumors arising in the head and neck include teratomas, adenocarcinomas, adenoid cystic carcinomas, and mucoepidermoid carcinomas. Rarer still are melanomas and lymphomas of the upper aerodigestive tract.
Alcohol and tobacco
Tobacco smoke is one of the main risk factors for head and neck cancer, and one of the most carcinogenic compounds in tobacco smoke is acrylonitrile. (See Tobacco smoking). Acrylonitrile appears to indirectly cause DNA damage by increasing oxidative stress, leading to increased levels of 8-oxo-2'-deoxyguanosine (8-oxo-dG) and formamidopyrimidine in DNA (see image). Both 8-oxo-dG and formamidopyrimidine are mutagenic. DNA glycosylase NEIL1 prevents mutagenesis by 8-oxo-dG and removes formamidopyrimidines from DNA.
However, cigarette smokers have a lifetime increased risk for head and neck cancers that is 5- to 25-fold increased over the general population. The ex-smoker's risk for squamous cell cancer of the head and neck begins to approach the risk in the general population twenty years after smoking cessation. The high prevalence of tobacco and alcohol use worldwide and the high association of these cancers with these substances makes them ideal targets for enhanced cancer prevention.
Other environmental carcinogens suspected of being potential causes of head and neck cancer include occupational exposures such as nickel refining, exposure to textile fibers, and woodworking. Use of marijuana, especially while younger, is linked to an increase in squamous-cell carcinoma cases while other studies suggest use is not shown to be associated with oral squamous cell carcinoma, or associated with decreased squamous cell carcinoma.
Excessive consumption of eggs, processed meats, and red meat were associated with increased rates of cancer of the head and neck in one study, while consumption of raw and cooked vegetables seemed to be protective.
Vitamin E was not found to prevent the development of leukoplakia, the white plaques that are the precursor for carcinomas of the mucosal surfaces, in adult smokers. Another study examined a combination of Vitamin E and beta carotene in smokers with early-stage cancer of the oropharynx, and found a worse prognosis in the vitamin users.
Some head and neck cancers are caused by human papillomavirus (HPV). In particular, HPV16 is a causal factor for some head and neck squamous-cell carcinoma (HNSCC). Approximately 15-25% of HNSCC contain genomic DNA from HPV, and the association varies based on the site of the tumor, especially HPV-positive oropharyngeal cancer, with highest distribution in the tonsils, where HPV DNA is found in (45 to 67%) of the cases, less often in the hypopharynx (13%–25%), and least often in the oral cavity (12%–18%) and larynx (3%–7%).
Some experts estimate that while up to 50% of cancers of the tonsil may be infected with HPV, only 50% of these are likely to be caused by HPV (as opposed to the usual tobacco and alcohol causes). The role of HPV in the remaining 25-30% is not yet clear. Oral sex is not risk free and results in a significant proportion of HPV-related head and neck cancer.
Positive HPV16 status is associated with improved prognosis over HPV-negative OSCC.
HPV can induce tumor by several mechanisms:
- E6 and E7 oncogenic proteins.
- Disruption of tumor suppressor genes.
- High-level DNA amplifications, for example, oncogenes.
- Generating alternative nonfunctional transcripts .
- interchromosomal rearrangements.
- Distinct host genome methylation and expression patterns, produced even when virus isn't integrated into the host genome.
Induction of cancer can be associated for the expression of viral oncoproteins, the most important E6 and E7, or other mechanisms many of them run by the integration such as the generation of altered transcripts, disruption of tumor suppressors, high levels of DNA amplifications, interchromosomial rearrangements, or changes in DNA methylation patterns, the latter being able to find even when the virus is identified in episomes. E6 sequesters p53 to promote p53 degradation while pRb inhibits E7. p53 prevents cell growth when DNA is damaged by activating apoptosis and p21, a kinase that blocks the formation of cyclin D / Cdk4 avoiding pRb phosphorylation and thereby prevents release of E2F is a transcription factor required for activation of genes involved in cell proliferation. pRb remains bound to E2F while this action phosphorylated preventing activation of proliferation. Therefore, E6 and E7 act synergistically in triggering cell cycle progression and therefore uncontrolled proliferation by inactivating the p53 and Rb tumor suppressors.
Viral integration tends to occur in or near oncogenes or tumor suppressor genes and it is for this reason that the integration of the virus can greatly contribute to the development of tumor characteristics.
Epstein–Barr virus (EBV) infection is associated with nasopharyngeal cancer. Nasopharyngeal cancer occurs endemically in some countries of the Mediterranean and Asia, where EBV antibody titers can be measured to screen high-risk populations. Nasopharyngeal cancer has also been associated with consumption of salted fish, which may contain high levels of nitrites.[medical citation needed]
Gastroesophageal reflux disease
The presence of acid reflux disease (gastroesophageal reflux disease [GERD]) or larynx reflux disease can also be a major factor. Stomach acids that flow up through the esophagus can damage its lining and raise susceptibility to throat cancer.
Hematopoietic stem cell transplantation
Patients after hematopoietic stem cell transplantation (HSCT) are at a higher risk for oral squamous cell carcinoma. Post-HSCT oral cancer may have more aggressive behavior with poorer prognosis, when compared to oral cancer in non-HSCT patients. This effect is supposed to be owing to the continuous lifelong immune suppression and chronic oral graft-versus-host disease.
Other possible causes
There are a wide variety of factors which can put someone at a heightened risk for throat cancer. Such factors include smoking or chewing tobacco or other things, such as gutkha, or paan, heavy alcohol consumption, poor diet resulting in vitamin deficiencies (worse if this is caused by heavy alcohol intake), weakened immune system, asbestos exposure, prolonged exposure to wood dust or paint fumes, exposure to petroleum industry chemicals, and being over the age of 55 years. Another risk factor includes the appearance of white patches or spots in the mouth, known as leukoplakia; in about ⅓ of the cases this develops into cancer. Other heightened risks: breathing or inhaling silica from cutting concrete, stone or cinder-blocks, especially in enclosed areas such as a warehouse, garage or basement.
A person usually presents to the physician complaining of one or more of the above symptoms. The person will typically undergo a needle biopsy of this lesion, and a histopathologic information is available, a multidisciplinary discussion of the optimal treatment strategy will be undertaken between the radiation oncologist, surgical oncologist, and medical oncologist.[medical citation needed]
Throat cancers are classified according to their histology or cell structure, and are commonly referred to by their location in the oral cavity and neck. This is because where the cancer appears in the throat affects the prognosis - some throat cancers are more aggressive than others depending upon their location. The stage at which the cancer is diagnosed is also a critical factor in the prognosis of throat cancer. Treatment guidelines recommend routine testing for the presence of HPV for all oropharyngeal squamous cell carcinoma tumours.
Squamous-cell carcinoma is a cancer of the squamous cell – a kind of epithelial cell found in both the skin and mucous membranes. It accounts for over 90% of all head and neck cancers, including more than 90% of throat cancer. Squamous cell carcinoma is most likely to appear in males over 40 years of age with a history of heavy alcohol use coupled with smoking.
The tumor marker Cyfra 21-1 may be useful in diagnosing squamous cell carcinoma of the head/neck (SCCHN).
Avoidance of recognised risk factors (as described above) is the single most effective form of prevention. Regular dental examinations may identify pre-cancerous lesions in the oral cavity.
When diagnosed early, oral, head and neck cancers can be treated more easily and the chances of survival increase tremendously. As of 2017 it was not known if existing HPV vaccines can help prevent head and neck cancer.
After a histologic diagnosis has been established and tumor extent determined, the selection of appropriate treatment for a specific cancer depends on a complex array of variables, including tumor site, relative morbidity of various treatment options, concomitant health problems, social and logistic factors, previous primary tumors, and the person's preference. Treatment planning generally requires a multidisciplinary approach involving specialist surgeons and medical and radiation oncologists.
Surgical resection and radiation therapy are the mainstays of treatment for most head and neck cancers and remain the standard of care in most cases. For small primary cancers without regional metastases (stage I or II), wide surgical excision alone or curative radiation therapy alone is used. More extensive primary tumors, or those with regional metastases (stage III or IV), planned combinations of pre- or postoperative radiation and complete surgical excision are generally used. More recently, as historical survival and control rates are recognized as less than satisfactory, there has been an emphasis on the use of various induction or concomitant chemotherapy regimens.
Surgery as a treatment is frequently used in most types of head and neck cancer. Usually the goal is to remove the cancerous cells entirely. This can be particularly tricky if the cancer is near the larynx and can result in the person being unable to speak. Surgery is also commonly used to resect (remove) some or all of the cervical lymph nodes to prevent further spread of the disease.
CO2 laser surgery is also another form of treatment. Transoral laser microsurgery allows surgeons to remove tumors from the voice box with no external incisions. It also allows access to tumors that are not reachable with robotic surgery. During the surgery, surgeon and pathologist work together to assess the adequacy of excision (“margin status”), minimizing the amount of normal tissue removed or damaged. This technique helps give the person as much speech and swallowing function as possible after surgery.
Radiation therapy is the most common form of treatment. There are different forms of radiation therapy, including 3D conformal radiation therapy, intensity-modulated radiation therapy, particle beam therapy and brachytherapy, which are commonly used in the treatments of cancers of the head and neck. Most people with head and neck cancer who are treated in the United States and Europe are treated with intensity-modulated radiation therapy using high energy photons. At higher doses, head and neck radiation is associated with thyroid dysfunction and pituitary axis dysfunction.
Chemotherapy in throat cancer is not generally used to cure the cancer as such. Instead, it is used to provide an inhospitable environment for metastases so that they will not establish in other parts of the body. Typical chemotherapy agents are a combination of paclitaxel and carboplatin. Cetuximab is also used in the treatment of throat cancer.
Docetaxel-based chemotherapy has shown a very good response in locally advanced head and neck cancer. Docetaxel is the only taxane approved by US FDA for head and neck cancer, in combination with cisplatin and fluorouracil for the induction treatment of inoperable, locally advanced squamous cell carcinoma of the head and neck.
While not specifically a chemotherapy, amifostine is often administered intravenously by a chemotherapy clinic prior to IMRT radiotherapy sessions. Amifostine protects the gums and salivary glands from the effects of radiation.
Photodynamic therapy may have promise in treating mucosal dysplasia and small head and neck tumors. Amphinex is giving good results in early clinical trials for treatment of advanced head and neck cancer.
Targeted therapy, according to the National Cancer Institute, is "a type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells without harming normal cells." Some targeted therapy used in squamous cell cancers of the head and neck include cetuximab, bevacizumab and erlotinib.
The best quality data are available for cetuximab since the 2006 publication of a randomized clinical trial comparing radiation treatment plus cetuximab versus radiation treatment alone. This study found that concurrent cetuximab and radiotherapy improves survival and locoregional disease control compared to radiotherapy alone, without a substantial increase in side effects, as would be expected with the concurrent chemoradiotherapy, which is the current gold standard treatment for advanced head and neck cancer. Whilst this study is of pivotal significance, interpretation is difficult since cetuximab-radiotherapy was not directly compared to chemoradiotherapy. The results of ongoing studies to clarify the role of cetuximab in this disease are awaited with interest.
Another study evaluated the impact of adding cetuximab to conventional chemotherapy (cisplatin) versus cisplatin alone. This study found no improvement in survival or disease-free survival with the addition of cetuximab to the conventional chemotherapy.
However, another study which completed in March 2007 found that there was an improvement in survival.
A 2010 review concluded that the combination of cetuximab and platin/5-fluorouracil should be considered the current standard first-line regimen.
Gendicine is a gene therapy that employs an adenovirus to deliver the tumor suppressor gene p53 to cells. It was approved in China in 2003 for the treatment of head and neck squamous cell carcinoma.
Immunotherapy is a type of treatment that activates the immune system to fight cancer. One type of immunotherapy, immune checkpoint blockade, binds to and blocks inhibitory signals on immune cells to release their anti-cancer activities.
In 2016, the FDA granted accelerated approval to pembrolizumab for the treatment of people with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. Later that year, the FDA approved nivolumab for the treatment of recurrent or metastatic HNSCC with disease progression on or after platinum-based chemotherapy. In 2019, the FDA approved pembrolizumab for the first-line treatment of metastatic or unresectable recurrent HNSCC.
Although early-stage head and neck cancers (especially laryngeal and oral cavity) have high cure rates, up to 50% of people with head and neck cancer present with advanced disease. Cure rates decrease in locally advanced cases, whose probability of cure is inversely related to tumor size and even more so to the extent of regional node involvement.
Consensus panels in America (AJCC) and Europe (UICC) have established staging systems for head and neck squamous-cell cancers. These staging systems attempt to standardize clinical trial criteria for research studies, and attempt to define prognostic categories of disease. Squamous cell cancers of the head and neck are staged according to the TNM classification system, where T is the size and configuration of the tumor, N is the presence or absence of lymph node metastases, and M is the presence or absence of distant metastases. The T, N, and M characteristics are combined to produce a “stage” of the cancer, from I to IVB.
Problem of second primaries
Survival advantages provided by new treatment modalities have been undermined by the significant percentage of people cured of head and neck squamous cell carcinoma (HNSCC) who subsequently develop second primary tumors. The incidence of second primary tumors ranges in studies from 9% to 23% at 20 years. Second primary tumors are the major threat to long-term survival after successful therapy of early-stage HNSCC. Their high incidence results from the same carcinogenic exposure responsible for the initial primary process, called field cancerization.
As it can impair a person’s ability to swallow and eat, throat cancer affects the digestive system. The difficulty in swallowing can lead to a person to choke on their food in the early stages of digestion and interfere with the food’s smooth travels down into the esophagus and beyond.
The treatments for throat cancer can also be harmful to the digestive system as well as other body systems. Radiation therapy can lead to nausea and vomiting, which can deprive a body of vital fluids (although these may be obtained through intravenous fluids if necessary). Frequent vomiting can lead to an electrolyte imbalance which has serious consequences for the proper functioning of the heart. Frequent vomiting can also upset the balance of stomach acids which has a negative impact on the digestive system, especially the lining of the stomach and esophagus.
In the cases of some throat cancers, the air passages in the mouth and behind the nose may become blocked from lumps or the swelling from the open sores. If the throat cancer is near the bottom of the throat, it has a high likelihood of spreading to the lungs and interfering with the person’s ability to breathe; this is even more likely if the person is a smoker, because they are highly susceptible to lung cancer.
Like any cancer, metastasization affects many areas of the body, as the cancer spreads from cell to cell and organ to organ. For example, if it spreads to the bone marrow, it will prevent the body from producing enough red blood cells and affects the proper functioning of the white blood cells and the body's immune system; spreading to the circulatory system will prevent oxygen from being transported to all the cells of the body; and throat cancer can throw the nervous system into chaos, making it unable to properly regulate and control the body.
Treatment side effects
Depending on the treatment used, People with head and neck cancer may experience the following symptoms and treatment side effects:
The number of new cases of head and neck cancers in the United States was 40,490 in 2006, accounting for about 3% of adult malignancies. A total of 11,170 people died of their disease in 2006. The worldwide incidence exceeds half a million cases annually. In North America and Europe, the tumors usually arise from the oral cavity, oropharynx, or larynx, whereas nasopharyngeal cancer is more common in the Mediterranean countries and in the Far East. In Southeast China and Taiwan, head and neck cancer, specifically nasopharyngeal cancer, is the most-common cause of death in young men.
- In 2008, there were 22,900 cases of oral cavity cancer, 12,250 cases of laryngeal cancer, and 12,410 cases of pharyngeal cancer in the United States.
- In 2002, 7,400 Americans were projected to die of these cancers.
- More than 70% of throat cancers are at an advanced stage when discovered.
- Men are 89% more likely than women to be diagnosed with, and are almost twice as likely to die of these cancers.
- African Americans are disproportionately affected by head and neck cancer, with younger ages of incidence, increased mortality, and more advanced disease at presentation. Laryngeal cancer incidence is higher in African Americans relative to white, Asian, and Hispanic populations. There is a lower survival rate for similar tumor states in African Americans with head and neck cancer.
- Smoking and tobacco use are directly related to oropharyngeal (throat) cancer deaths.
- Head and neck cancer increases with age, especially after 50 years. Most people are between 50 and 70 years old.
Immunotherapy with immune checkpoint inhibitors is being investigated in head and neck cancers.
- "Head and Neck Cancers". NCI. March 29, 2017. Retrieved 17 September 2017.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.8. ISBN 978-9283204299.
- GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- "SEER Stat Fact Sheets: Oral Cavity and Pharynx Cancer". SEER. April 2016. Archived from the original on 15 November 2016. Retrieved 29 September 2016.
- Beyzadeoglu, Murat; Ozyigit, Gokhan; Selek, Ugur (2014). Radiation Therapy for Head and Neck Cancers: A Case-Based Review. Springer. p. 18. ISBN 9783319104133. Archived from the original on 2017-09-10.
- O’Rorke, M.A.; Ellison, M.V.; Murray, L.J.; Moran, M.; James, J.; Anderson, L.A. (December 2012). "Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis". Oral Oncology. 48 (12): 1191–1201. doi:10.1016/j.oraloncology.2012.06.019. PMID 22841677. Archived (PDF) from the original on 2017-09-10.
- Ragin, Camille C. R.; Taioli, Emanuela (15 October 2007). "Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis". International Journal of Cancer. 121 (8): 1813–1820. doi:10.1002/ijc.22851. PMID 17546592.
- Krishnatreya, M; Rahman, T; Kataki, AC; Das, A; Das, AK; Lahkar, K (2013). "Synchronous primary cancers of the head and neck region and upper aero digestive tract: defining high-risk patients". Indian Journal of Cancer. 50 (4): 322–6. doi:10.4103/0019-509x.123610. PMID 24369209.
- Ridge JA, Glisson BS, Lango MN, et al. "Head and Neck Tumors" Archived 2009-07-20 at the Wayback Machine in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach Archived 2013-10-04 at the Wayback Machine. 11 ed. 2008.
- Cunningham FH, Fiebelkorn S, Johnson M, Meredith C (2011). "A novel application of the Margin of Exposure approach: segregation of tobacco smoke toxicants". Food Chem. Toxicol. 49 (11): 2921–33. doi:10.1016/j.fct.2011.07.019. PMID 21802474.
- Pu X, Kamendulis LM, Klaunig JE (2009). "Acrylonitrile-induced oxidative stress and oxidative DNA damage in male Sprague-Dawley rats". Toxicol. Sci. 111 (1): 64–71. doi:10.1093/toxsci/kfp133. PMC 2726299. PMID 19546159.
- Kalam MA, Haraguchi K, Chandani S, Loechler EL, Moriya M, Greenberg MM, Basu AK (2006). "Genetic effects of oxidative DNA damages: comparative mutagenesis of the imidazole ring-opened formamidopyrimidines (Fapy lesions) and 8-oxo-purines in simian kidney cells". Nucleic Acids Res. 34 (8): 2305–15. doi:10.1093/nar/gkl099. PMC 1458282. PMID 16679449.
- Jena NR, Mishra PC (2013). "Is FapyG mutagenic?: Evidence from the DFT study". ChemPhysChem. 14 (14): 3263–70. doi:10.1002/cphc.201300535. PMID 23934915.
- Suzuki T, Harashima H, Kamiya H (2010). "Effects of base excision repair proteins on mutagenesis by 8-oxo-7,8-dihydroguanine (8-hydroxyguanine) paired with cytosine and adenine". DNA Repair (Amst.). 9 (5): 542–50. doi:10.1016/j.dnarep.2010.02.004. hdl:2115/43021. PMID 20197241.
- Nemec AA, Wallace SS, Sweasy JB (2010). "Variant base excision repair proteins: contributors to genomic instability". Semin. Cancer Biol. 20 (5): 320–8. doi:10.1016/j.semcancer.2010.10.010. PMC 3254599. PMID 20955798.
- Andre K, Schraub S, Mercier M, Bontemps P (1995). "Role of alcohol and tobacco in the aetiology of head and neck cancer: a case-control study in the Doubs region of France". Eur J Cancer B Oral Oncol. 31B (5): 301–9. doi:10.1016/0964-1955(95)00041-0. PMID 8704646.
- Winn D (1992). Smokeless tobacco and aerodigestive tract cancers: recent research directions. Adv Exp Med Biol. Advances in Experimental Medicine and Biology. 320. pp. 39–46. doi:10.1007/978-1-4615-3468-6_6. ISBN 978-0-306-44244-5. PMID 1442283.
- Iribarren C, Tekawa I, Sidney S, Friedman G (1999). "Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men". N Engl J Med. 340 (23): 1773–80. CiteSeerX 10.1.1.460.1056. doi:10.1056/NEJM199906103402301. PMID 10362820.
- Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz SP (1999). "Marijuana use and increased risk of squamous cell carcinoma of the head and neck". Cancer Epidemiology, Biomarkers & Prevention. 8 (12): 1071–1078. PMID 10613339.
- Rosenblatt KA (2004). "Marijuana use and risk of oral squamous cell carcinoma". Cancer Res. 64 (11): 4049–54. doi:10.1158/0008-5472.CAN-03-3425. PMID 15173020.
- Liang C (2009). "A population-based case-control study of marijuana use and head and neck squamous cell carcinoma". Cancer Prev Res (Phila Pa). 2 (8): 759–68. doi:10.1158/1940-6207.CAPR-09-0048. PMC 2812803. PMID 19638490.
- Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S, Monnier P (1998). "Food groups and risk of oral and pharyngeal cancer". Int J Cancer. 77 (5): 705–9. doi:10.1002/(SICI)1097-0215(19980831)77:5<705::AID-IJC8>3.0.CO;2-Z. PMID 9688303.
- Liede K, Hietanen J, Saxen L, Haukka J, Timonen T, Häyrinen-Immonen R, Heinonen O (1998). "Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers". Oral Dis. 4 (2): 78–83. doi:10.1111/j.1601-0825.1998.tb00261.x. PMID 9680894.
- Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F, Mercier J, Têtu B, Harel F, Mâsse B, Vigneault E, Vass S, del Vecchio P, Roy J (2005). "A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients". J Natl Cancer Inst. 97 (7): 481–8. doi:10.1093/jnci/dji095. PMID 15812073.
- Jeng J, Chang M, Hahn L (2001). "Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives". Oral Oncol. 37 (6): 477–92. doi:10.1016/S1368-8375(01)00003-3. PMID 11435174.
- "Biomarkers for Cancers of the Head and Neck". Retrieved 2014-08-07.
- D'Souza, G.; Kreimer, A.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.; Westra, W.; Gillison, M. (May 2007). "Case-control study of human papillomavirus and oropharyngeal cancer". The New England Journal of Medicine. 356 (19): 1944–1956. doi:10.1056/NEJMoa065497. ISSN 0028-4793. PMID 17494927.
- Kreimer, A.; Clifford, G.; Boyle, P.; Franceschi, S. (Feb 2005). "Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review". Cancer Epidemiology, Biomarkers & Prevention. 14 (2): 467–475. doi:10.1158/1055-9965.EPI-04-0551. PMID 15734974.
- Joseph, Andrew W. (2012). "Epidemiology of Human Papillomavirus-Related Head and Neck Cancer". Otolaryngologic Clinics of North America. 45 (4): 739–764. doi:10.1016/j.otc.2012.04.003. PMID 22793850.
- Perez-Ordoñez, B.; Beauchemin, M.; Jordan, R. (May 2006). "Molecular biology of squamous cell carcinoma of the head and neck". Journal of Clinical Pathology. 59 (5): 445–453. doi:10.1136/jcp.2003.007641. ISSN 0021-9746. PMC 1860277. PMID 16644882.
- Paz, I. B.; Cook, N.; Odom-Maryon, T.; Xie, Y.; Wilczynski, S. P. (1997). "Human papillomavirus (HPV) in head and neck cancer". Cancer. 79 (3): 595–604. doi:10.1002/(SICI)1097-0142(19970201)79:3<595::AID-CNCR24>3.0.CO;2-Y. PMID 9028373.
- Hobbs, C.G.L.; Sterne, J.A.C.; Bailey, M.; Heyderman, R.S.; Birchall, M.A.; Thomas, S.J. (August 2006). "Human papillomavirus and head and neck cancer: a systematic review and meta-analysis" (PDF). Clinical Otolaryngology. 31 (4): 259–266. doi:10.1111/j.1749-4486.2006.01246.x. PMID 16911640. Archived (PDF) from the original on 2017-08-11.
- Weinberger; Yu, Z; Haffty, BG; Kowalski, D; Harigopal, M; Brandsma, J; Sasaki, C; Joe, J; et al. (2006). "Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers With Favorable Prognosis". Journal of Clinical Oncology. 24 (5): 736–47. doi:10.1200/JCO.2004.00.3335. PMID 16401683. Archived from the original on 2009-01-20.
- Haddad, Robert I., MD (2007). "Human Papillomavirus Infection and Oropharyngeal Cancer" (PDF). Archived (PDF) from the original on 2012-05-13.CS1 maint: multiple names: authors list (link)
- Tahtali, A.; Hey, C; Geissler, C; Filman, N; Diensthuber, N; Leinung, M; Stöver, T; Wagenblast, J; et al. (2013). "HPV status and overall survival of patients with oropharyngeal squamous cell carcinoma--a retrospective study of a German head and neck cancer center". Anticancer Research. 33 (8): 3481–5. PMID 23898123. Archived from the original on 2016-01-07.
- Schmitz, M. (2012). "Loss of gene function as a consequence of human papillomavirus DNA integration". International Journal of Cancer. 131 (5): E593–E602. doi:10.1002/ijc.27433. PMID 22262398.
- Parfenov, Michael (2014). "Characterization of HPV and host genome interactions in primary head and neck cancers". Proceedings of the National Academy of Sciences. 111 (43): 15544–15549. doi:10.1073/pnas.1416074111. PMC 4217452. PMID 25313082.
- 
- Elad S, Zadik Y, Zeevi I, et al. (December 2010). "Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence". Transplantation. 90 (11): 1243–4. doi:10.1097/TP.0b013e3181f9caaa. PMID 21119507.
- "Routine HPV Testing in Head and Neck Squamous Cell Carcinoma. EBS 5-9". May 2013. Archived from the original on 30 September 2016. Retrieved 22 May 2017.
- Haines, GK 3rd (24 May 2013). "Pathology of Head and Neck Cancers I: Epithelial and Related Tumors". In Radosevich, JA (ed.). Head & Neck Cancer: Current Perspectives, Advances, and Challenges. Springer Science & Business Media. pp. 257–87. ISBN 978-94-007-5827-8. Archived from the original on 7 January 2016.
- Wang, Y. X.; Hu, D.; Yan, X. (2013). "Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: A meta-analysis". European Review for Medical and Pharmacological Sciences. 17 (17): 2383–2389. PMID 24065233.
- Al-Sarraf M (2002). "Treatment of locally advanced head and neck cancer: historical and critical review". Cancer Control. 9 (5): 387–99. doi:10.1177/107327480200900504. PMID 12410178.
- Maxwell, JH; Thompson, LD; Brandwein-Gensler, MS; Weiss, BG; Canis, M; Purgina, B; Prabhu, AV; Lai, C; Shuai, Y; Carroll, WR; Morlandt, A; Duvvuri, U; Kim, S; Johnson, JT; Ferris, RL; Seethala, R; Chiosea, SI (1 December 2015). "Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control". JAMA Otolaryngology–Head & Neck Surgery. 141 (12): 1104–10. doi:10.1001/jamaoto.2015.1351. PMC 5242089. PMID 26225798.
-  Archived March 5, 2012, at the Wayback Machine
- Mahmood SS (2016). "Cardiovascular Complications of Cranial and Neck Radiation". Current Treatment Options in Cardiovascular Medicine. 18 (45): 45. doi:10.1007/s11936-016-0468-4. PMID 27181400.
- "FDA Approval for Docetaxel - National Cancer Institute". Cancer.gov. Archived from the original on 2014-09-01. Retrieved 2014-08-07.
- "Inoperable cancers killed by new laser surgery" The Times. UK. 3-April-2010 p15
- Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R, Jones C, Sur R, Raben D, Jassem J, Ove R, Kies M, Baselga J, Youssoufian H, Amellal N, Rowinsky E, Ang K (2006). "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck". N Engl J Med. 354 (6): 567–78. doi:10.1056/NEJMoa053422. PMID 16467544.
- Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere A (2005). "Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study". J Clin Oncol. 23 (34): 8646–54. doi:10.1200/JCO.2005.02.4646. PMID 16314626.
- Specenier, Pol; Vermorken, Jan B (2014-07-08). "Advances in the systemic treatment of head and neck cancers". Current Opinion in Oncology. 22 (3): 200–205. doi:10.1097/CCO.0b013e3283376e15. PMID 20154619. Archived from the original on 2014-08-08. Retrieved 2014-08-07.
- Pearson S, Jia H, Kandachi K (2004). "China approves first gene therapy". Nature Biotechnology. 22 (1): 3–4. doi:10.1038/nbt0104-3. PMID 14704685. Archived from the original on 2014-08-28.
- Lechner M, Frampton GM, Fenton T, et al. (2013). "Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors". Genome Medicine. 5 (5): 49. doi:10.1186/gm453. PMC 4064312. PMID 23718828.
- Research, Center for Drug Evaluation and (2019-02-09). "pembrolizumab (KEYTRUDA)". FDA.
- Research, Center for Drug Evaluation and (2018-11-03). "Nivolumab for SCCHN". FDA.
- Research, Center for Drug Evaluation and (2019-06-11). "FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma". FDA.
- Gourin C, Podolsky R (2006). "Racial disparities in patients with head and neck squamous cell carcinoma". Laryngoscope. 116 (7): 1093–106. doi:10.1097/01.mlg.0000224939.61503.83. PMID 16826042.
- Iro H, Waldfahrer F (1998). "Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients". Cancer. 83 (10): 2201–7. doi:10.1002/(SICI)1097-0142(19981115)83:10<2201::AID-CNCR20>3.0.CO;2-7. PMID 9827726.
- Jones A, Morar P, Phillips D, Field J, Husband D, Helliwell T (1995). "Second primary tumors in patients with head and neck squamous cell carcinoma". Cancer. 75 (6): 1343–53. doi:10.1002/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T. PMID 7882285.
- Cooper J, Pajak T, Rubin P, Tupchong L, Brady L, Leibel S, Laramore G, Marcial V, Davis L, Cox J (1989). "Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience". Int J Radiat Oncol Biol Phys. 17 (3): 449–56. doi:10.1016/0360-3016(89)90094-1. PMID 2674073.
- Priante AV, Castilho EC, Kowalski LP (April 2011). "Second primary tumors in patients with head and neck cancer". Current Oncology Reports. 13 (2): 132–7. doi:10.1007/s11912-010-0147-7. PMID 21234721.
- "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 2009-11-11. Retrieved Nov 11, 2009.
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M (2006). "Cancer statistics, 2006". CA Cancer J Clin. 56 (2): 106–30. doi:10.3322/canjclin.56.2.106. PMID 16514137.
- Titcomb C (2001). "High incidence of nasopharyngeal carcinoma in Asia". J Insur Med. 33 (3): 235–8. PMID 11558403.
- Cancer Facts and Figures,  Archived 2007-09-29 at the Wayback Machine, American Cancer Society 2002.
- Throat Cancer patient information web page, "Archived copy". Archived from the original on 2007-07-01. Retrieved 2007-06-17.CS1 maint: archived copy as title (link), NCH Healthcare Systems, 1999
- Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General, U. S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1989.
- Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
|Wikimedia Commons has media related to Head and neck cancer.|
- Head and Neck Cancer at MedlinePlus (National Library of Medicine)
- Head and Neck Cancer Treatment at RadiologyInfo
- Head and Neck Cancer at Cancer.net (American Society of Clinical Oncology)